The Enterprise Value as of November 2024 (TTM) for REGENXBIO Inc. (RGNX) is 535.38M

According to REGENXBIO Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 535.38M. This represents a change of -35.28% compared to the average of 827.22M of the last 4 quarters.

REGENXBIO Inc. (RGNX) Historical Enterprise Value (quarterly & annually)

How has RGNX Enterprise Value performed in the past?

The mean historical Enterprise Value of REGENXBIO Inc. over the last ten years is 919.30M. The current 535.38M Enterprise Value has changed 5.72% with respect to the historical average. Over the past ten years (40 quarters), RGNX's Enterprise Value was at its highest in in the September 2018 quarter at 2.41B. The Enterprise Value was at its lowest in in the September 2015 quarter at -99381730.00.

REGENXBIO Inc. (RGNX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of REGENXBIO Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

REGENXBIO Inc. (RGNX) Average Enterprise Value

How has RGNX Enterprise Value performed in the past?

The current Enterprise Value of REGENXBIO Inc. (RGNX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

REGENXBIO Inc. (RGNX) Enterprise Value vs. Peers

How is RGNX’s Enterprise Value compared to its peers?

REGENXBIO Inc.’s Enterprise Value is less than Day One Biopharmaceuticals, Inc. (1.08B), less than Replimune Group, Inc. (748.93M), less than Mirum Pharmaceuticals, Inc. (2.02B), less than Rocket Pharmaceuticals, Inc. (1.52B), less than Avidity Biosciences, Inc. (4.70B), greater than uniQure N.V. (517.08M), less than Protagonist Therapeutics, Inc. (2.41B), less than Pliant Therapeutics, Inc. (862.98M), less than Immunocore Holdings plc (1.53B), less than Revolution Medicines, Inc. (9.09B), greater than Monte Rosa Therapeutics, Inc. (481.42M), greater than Stoke Therapeutics, Inc. (496.70M), greater than AN2 Therapeutics, Inc. (5.46M), greater than Passage Bio, Inc. (38.74M), greater than 4D Molecular Therapeutics, Inc. (251.01M), less than Crinetics Pharmaceuticals, Inc. (4.88B), greater than LianBio (-66141903.00), greater than Kezar Life Sciences, Inc. (41.28M),

Build a custom stock screener for REGENXBIO Inc. (RGNX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like REGENXBIO Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

REGENXBIO Inc. (RGNX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like REGENXBIO Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.